CD8A and neoplasm: An immune score based on the four-density percentile mean of two markers (CD3+ and CD8+) and two regions (tumor and invasive marginal regions) has been internationally recognized as a risk assessment tool for colon cancer, illustrating the potential importance of evaluating tumor immune infiltration in guiding clinical decision making (14).